Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
OBJECTIVES: The purpose of this study was to evaluate whether 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging predicts ventricular arrhythmias causing appropriate implantable cardioverter-defibrillator (ICD) therapy (primary end point) and the composite of appropriate ICD therapy or cardiac death (secondary end point).
BACKGROUND: Although cardiac sympathetic denervation is associated with ventricular arrhythmias, limited data are available on the predictive value of sympathetic nerve imaging with 123-I MIBG on the occurrence of arrhythmias.
METHODS: Before ICD implantation, patients underwent 123-I MIBG and myocardial perfusion imaging. Early and late 123-I MIBG (planar and single-photon emission computed tomography [SPECT]) imaging was performed to assess cardiac innervation (heart-to-mediastinum ratio, cardiac washout rate, and 123-I MIBG SPECT defect score). Stress-rest myocardial perfusion imaging was performed to assess myocardial infarction and perfusion abnormalities (perfusion defect scores). During follow-up, appropriate ICD therapy and cardiac death were documented.
RESULTS: One-hundred sixteen heart failure patients referred for ICD therapy were enrolled. During a mean follow-up of 23 +/- 15 months, appropriate ICD therapy (primary end point) was documented in 24 (21%) patients and appropriate ICD therapy or cardiac death (secondary end point) in 32 (28%) patients. Late 123-I MIBG SPECT defect score was an independent predictor for both end points. Patients with a large late 123-I MIBG SPECT defect (summed score >26) showed significantly more appropriate ICD therapy (52% vs. 5%, p < 0.01) and appropriate ICD therapy or cardiac death (57% vs. 10%, p < 0.01) than patients with a small defect (summed score </=26) at 3-year follow-up.
CONCLUSIONS: Cardiac sympathetic denervation predicts ventricular arrhythmias causing appropriate ICD therapy as well as the composite of appropriate ICD therapy or cardiac death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 55(2010), 24 vom: 15. Juni, Seite 2769-77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boogers, Mark J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3-Iodobenzylguanidine |
|---|
| Anmerkungen: |
Date Completed 06.07.2010 Date Revised 25.11.2016 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacc.2009.12.066 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM198724101 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM198724101 | ||
| 003 | DE-627 | ||
| 005 | 20231223213251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2009.12.066 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0662.xml |
| 035 | |a (DE-627)NLM198724101 | ||
| 035 | |a (NLM)20538172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boogers, Mark J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2010 | ||
| 500 | |a Date Revised 25.11.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: The purpose of this study was to evaluate whether 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging predicts ventricular arrhythmias causing appropriate implantable cardioverter-defibrillator (ICD) therapy (primary end point) and the composite of appropriate ICD therapy or cardiac death (secondary end point) | ||
| 520 | |a BACKGROUND: Although cardiac sympathetic denervation is associated with ventricular arrhythmias, limited data are available on the predictive value of sympathetic nerve imaging with 123-I MIBG on the occurrence of arrhythmias | ||
| 520 | |a METHODS: Before ICD implantation, patients underwent 123-I MIBG and myocardial perfusion imaging. Early and late 123-I MIBG (planar and single-photon emission computed tomography [SPECT]) imaging was performed to assess cardiac innervation (heart-to-mediastinum ratio, cardiac washout rate, and 123-I MIBG SPECT defect score). Stress-rest myocardial perfusion imaging was performed to assess myocardial infarction and perfusion abnormalities (perfusion defect scores). During follow-up, appropriate ICD therapy and cardiac death were documented | ||
| 520 | |a RESULTS: One-hundred sixteen heart failure patients referred for ICD therapy were enrolled. During a mean follow-up of 23 +/- 15 months, appropriate ICD therapy (primary end point) was documented in 24 (21%) patients and appropriate ICD therapy or cardiac death (secondary end point) in 32 (28%) patients. Late 123-I MIBG SPECT defect score was an independent predictor for both end points. Patients with a large late 123-I MIBG SPECT defect (summed score >26) showed significantly more appropriate ICD therapy (52% vs. 5%, p < 0.01) and appropriate ICD therapy or cardiac death (57% vs. 10%, p < 0.01) than patients with a small defect (summed score </=26) at 3-year follow-up | ||
| 520 | |a CONCLUSIONS: Cardiac sympathetic denervation predicts ventricular arrhythmias causing appropriate ICD therapy as well as the composite of appropriate ICD therapy or cardiac death | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a 3-Iodobenzylguanidine |2 NLM | |
| 650 | 7 | |a 35MRW7B4AD |2 NLM | |
| 700 | 1 | |a Borleffs, C Jan Willem |e verfasserin |4 aut | |
| 700 | 1 | |a Henneman, Maureen M |e verfasserin |4 aut | |
| 700 | 1 | |a van Bommel, Rutger J |e verfasserin |4 aut | |
| 700 | 1 | |a van Ramshorst, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Boersma, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Dibbets-Schneider, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Stokkel, Marcel P |e verfasserin |4 aut | |
| 700 | 1 | |a van der Wall, Ernst E |e verfasserin |4 aut | |
| 700 | 1 | |a Schalij, Martin J |e verfasserin |4 aut | |
| 700 | 1 | |a Bax, Jeroen J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 55(2010), 24 vom: 15. Juni, Seite 2769-77 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2010 |g number:24 |g day:15 |g month:06 |g pages:2769-77 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2009.12.066 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2010 |e 24 |b 15 |c 06 |h 2769-77 | ||